Merger control alongside investment screening: what to do in the first ten days is answered by treating the two regimes as separate clocks that start running the moment signing occurs: freeze any conditions precedent that assume a single clearance, confirm within days whether either regime is triggered, and do not close on the assumption that one filing covers both.
Who this concerns
Boards and deal teams executing an acquisition, subscription, or restructuring where the target, the acquirer, or the underlying assets sit inside Sweden, and the transaction is large enough, or sensitive enough, to draw the attention of more than one authority. This includes buyers domiciled outside the EU or EEA acquiring a stake in a Swedish company active in infrastructure, defence-adjacent supply, telecoms, energy, or critical technology, and it includes any transaction crossing a turnover threshold that brings it within the competition authority's remit regardless of where the buyer sits. It also concerns minority co-investors and financing parties whose closing conditions are drafted around a single clearance event that, in practice, does not exist, a situation covered in more depth across the corporate investment screening practice.
What the law says
Sweden runs two separate and formally independent notification regimes that can apply to the same transaction. One is competition-based merger control, administered by the Swedish Competition Authority, testing whether the concentration reduces competition in a relevant market. The other is investment screening, administered by the Inspectorate of Strategic Products, testing whether the transaction places sensitive activities, technology, or infrastructure under foreign control in a way that affects security or public order. Under Swedish law as it currently stands, meeting the threshold for one regime says nothing about the other: a transaction can be cleared, exempted, or entirely outside the scope of merger control and still require a screening filing, and the reverse is equally possible. There is no combined form, no single competent authority, and no assumption that clearance under one regime substitutes for the other.
The practical consequence for a deal team is that "notification" is not a single milestone on the closing timetable. It is at least two separate assessments, each with its own trigger test, its own authority, and its own consequences for closing before clearance is obtained.
How it works in practice
Day one: freeze the closing mechanics before you file anything
The first task is not filing, it is stopping the deal team from closing on autopilot. Any long-form share purchase agreement drafted before this question was raised will usually condition completion on "receipt of all necessary regulatory approvals" as a single defined term. That drafting assumes a single clearance event. Before anything else happens, confirm in writing between the parties that completion is conditional on both regimes separately, with an outside date long enough to accommodate the slower of the two.
Days one to three: map which regime actually applies
Run the merger control test and the screening test as two independent exercises, not as one combined check. The merger control test looks at turnover and market overlap between the parties. The screening test looks at what the target does, not how big it is: a small target with sensitive activity in energy distribution, port infrastructure, or dual-use technology can trigger a mandatory screening filing while falling comfortably below any merger control threshold. Neither test defers to the other's outcome.
What to check before day five
- Whether the acquirer's ultimate beneficial owner, not just the signing entity, sits outside the EU or EEA
- Whether the target's activity falls within any of the sensitive categories used for screening, regardless of the target's size
- Whether the transaction structure, an asset deal, a share deal, or a staged acquisition of control, changes which regime applies
- Whether the signing entity is a special purpose vehicle whose parent has not itself been assessed
- Whether the financing structure introduces a separate foreign investor with its own screening exposure
- Whether the closing conditions in the signed agreement already assume a single clearance
Who inside the organisation needs to know by day ten
General counsel, the deal lead, and the board member sponsoring the transaction need to agree, within the same ten days, on who owns the screening filing and who owns the merger control filing. The two are frequently run by different external advisers on different timelines, and a gap between the two workstreams is where slippage most often originates rather than in either filing on its own.
Sequencing the filings
Where both regimes apply, the filings do not have to be simultaneous, but treating them as sequential by default usually costs time rather than saves it. A screening filing raises questions the competition file does not, and a competition file can proceed on a track that has nothing to do with security concerns. Coordinating the two submissions, so that neither authority reads facts about the transaction for the first time from the other authority's file, is a drafting and sequencing exercise that has to start inside the first ten days, not once one clearance is already in hand.
The gun-jumping risk during the review window
Closing, or taking any step that gives the acquirer influence over the target's commercial decisions before clearance, is treated as a breach of standstill under merger control and can independently trigger enforcement exposure under screening rules, even where the underlying transaction would ultimately have been cleared. Integration planning, shared management reporting, and any exchange of competitively sensitive information between signing and closing need to be walled off before day ten, not reviewed for compliance after the fact.
Cross-border ownership and financing
Where the acquirer, its parent, or its financing sits outside Sweden, the screening test looks through the signing entity to whoever ultimately controls it. A Swedish-incorporated buyer with a non-EU ultimate owner does not avoid the test by virtue of where the buyer itself is registered. Where the target has its own foreign subsidiaries or where the deal is financed through a foreign lender taking security over Swedish assets, the review may also need to account for how those other jurisdictions treat the same transaction, including whether a Swedish court judgment arising from a later dispute over the deal would need to be recognised abroad rather than assumed enforceable by default.
Where the target has minority shareholders
A screening or merger control filing does not suspend the target's own corporate mechanics. Minority shareholders who are being squeezed out, or who are disputing the valuation used in the transaction, run on a separate timetable governed by minority protection and squeeze-out rules, and that dispute can surface in the middle of a screening review if the acquirer's stated intentions for the target change as a result of conditions imposed by either authority.
Can a transaction be cleared under merger control but still blocked under investment screening?
Yes. The two tests measure different things and neither authority's clearance binds the other. A transaction with no competition overlap at all can still be prohibited or conditioned under screening if the target's activity falls within a protected category, and a transaction cleared under screening can still be blocked on competition grounds if the parties compete in the same market.
Is there a single filing that covers both merger control and investment screening in Sweden?
No. Under Swedish law as it currently stands, the two regimes are administered by different authorities using different forms, different trigger tests, and different timelines. A filing made to one authority does not put the transaction on the other authority's radar automatically, which is why parties sometimes discover a screening obligation only after merger clearance has already been obtained.
What happens if closing occurs before both clearances are obtained?
The consequences depend on which regime was breached and how. Closing before merger clearance in a case where clearance was required can expose the transaction to unwinding and the parties to separate enforcement action, independent of whether the deal would eventually have been approved. Closing before a required screening clearance carries its own separate exposure, again independent of the underlying merits of the transaction.
The numbers
No fixed number of days, no fixed fee, and no fixed threshold can usefully be quoted here without reference to the specific situation and the specific authority handling it, and doing so would create a false sense of certainty that the file itself will not support. What can be said is what drives the figures in a specific case: the number of jurisdictions in which the acquirer's ownership chain has to be disclosed, whether the target's activity sits close to the boundary of a sensitive category rather than clearly inside or outside it, whether either authority requests a second round of information, and whether remedies or conditions are negotiated rather than accepted outright. A transaction with a clean, single-jurisdiction ownership chain and an activity clearly outside any sensitive category moves through both regimes considerably faster than one where either fact is in doubt. Cost follows the same logic: it is driven by the number of authorities involved and the number of rounds of questions, not by the size of the transaction on its own.
Where it usually goes wrong
The most common failure is assuming that clearing the larger or more obvious regime disposes of the smaller one. Deal teams that spend their attention on merger control because the transaction value is large often treat screening as a formality, precisely because the target looks too small to matter under a turnover test that has nothing to do with what the target actually does.
The second failure is assuming that EU domicile of the buyer is itself a shield. Screening tests look at the ultimate owner, not the nearest holding company, so a buyer incorporated inside the EU with capital or control originating outside it does not automatically fall outside scope.
The third is drafting conditions precedent around "regulatory approval" as a single defined term, which then has to be renegotiated under time pressure once it becomes clear that two separate clearances, on two separate timelines, are actually required.
The fourth is treating informal contact with an authority, made to test the waters before a formal filing, as equivalent to a clearance or a comfort letter. It is neither, and it does not stop the standstill obligation from applying once signing has occurred.
The fifth is assuming that because a target has previously been the subject of foreign investment without triggering screening, a materially similar transaction today will be treated the same way. Screening categories and enforcement posture are not static, and a prior transaction that went unexamined is not authority for how the next one will be treated.
None of this changes where the target has a supply relationship with a public sector counterparty whose contract terms already specify which court or authority is competent in the event of delivery failure; that question sits alongside, not inside, the screening and merger control analysis, and confusing the two review tracks with contractual dispute mechanics is a common source of delay in its own right. A transaction structured as an internal reorganisation ahead of a sale carries a parallel set of tax treatment deadlines that run independently of either clearance and are frequently missed because attention is fixed on the regulatory filings.
What to do next
The first ten days establish whether the transaction faces one regime, two, or neither, and whether the signed agreement's conditions precedent match that answer. That mapping exercise is something a deal team can usually complete on its own.
A related but separate problem arises where the transaction itself triggers a dispute among existing shareholders about the structure chosen to satisfy both regimes: shareholder conflicts inside a Swedish limited company run on their own mechanics and are worth flagging early rather than discovering mid-transaction.
Where the ten-day mapping shows overlapping exposure and the outside date is tight, an assessment of the specific filing strategy, book one here, is the point at which self-directed mapping stops being sufficient and a transaction-specific read of both regimes begins.